Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Ricalizumab After PCI in Extremely High-Risk ASCVD
ChiCTR2600125281Phase 4Not yet recruiting
- Sponsor
- Yunnan Zhongnan Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of recaticimab in atherosclerotic disease (3 arms), sponsored by Yunnan Zhongnan Hospital. Primary endpoints: blood glucose, total cholesterol and 4 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
recaticimab
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2600125281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125281.